ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
-0,61%
Bitcoin
69 372,18
-1,97%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Actualités

AQST

Aquestive Therapeutics (AQST)

Aquestive Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AQST
DateHeureSourceTitreSymboleSociété
07/06/202414h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AQSTAquestive Therapeutics Inc
03/06/202414h00GlobeNewswire Inc.Aquestive Therapeutics Announces Executive Appointments and Builds Commercial CapabilitiesNASDAQ:AQSTAquestive Therapeutics Inc
28/05/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
13/05/202419h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
09/05/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
07/05/202422h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AQSTAquestive Therapeutics Inc
07/05/202422h19GlobeNewswire Inc.Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
29/04/202413h00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
25/04/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
12/04/202422h01GlobeNewswire Inc.Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyNASDAQ:AQSTAquestive Therapeutics Inc
01/04/202414h00GlobeNewswire Inc.Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveNASDAQ:AQSTAquestive Therapeutics Inc
25/03/202413h00GlobeNewswire Inc.Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
20/03/202402h49GlobeNewswire Inc.Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
19/03/202421h01GlobeNewswire Inc.Aquestive Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
14/03/202422h23GlobeNewswire Inc.Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA MeetingNASDAQ:AQSTAquestive Therapeutics Inc
08/03/202422h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
05/03/202423h12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AQSTAquestive Therapeutics Inc
05/03/202423h05GlobeNewswire Inc.Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
21/02/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
14/02/202421h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AQSTAquestive Therapeutics Inc
12/02/202423h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AQSTAquestive Therapeutics Inc
30/01/202414h00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
05/12/202314h00GlobeNewswire Inc.Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
10/11/202314h00GlobeNewswire Inc.Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
06/11/202322h37GlobeNewswire Inc.Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
02/11/202313h00GlobeNewswire Inc.Aquestive Therapeutics Completes $45 Million Debt RefinancingNASDAQ:AQSTAquestive Therapeutics Inc
31/10/202313h00GlobeNewswire Inc.Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
09/10/202314h00GlobeNewswire Inc.Aquestive Therapeutics Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
02/10/202322h18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AQSTAquestive Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AQST

Dernières Valeurs Consultées

BIT
UB6VG9
Unicredit Bank
NASDAQ
FNSCE
LSE
TR65
0 1/8% Il Tg 65
BIT
UC1H0A
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés